董事, 10% 持股人
David P. Bonita, M.D. is a seasoned healthcare investor and board director, currently serving as an Independent Director at ImageneBio, Inc. (IMA) since 2025, alongside roles at Acutus Medical, Inc. (since 2016), Prelude Therapeutics, Inc. (since 2016), Repare Therapeutics, Inc. (since 2019), Third Harmonic Bio, Inc. (since 2020), and others, including as General Partner at OrbiMed Advisors Private Equity since 2020.[[1]](https://www.marketscreener.com/insider/DAVID-BONITA-A077UI/)[[3]](https://preludetx.com/david-bonita-md/)[[4]](https://imagenebio.com/team/david-p-bonita-m-d/)
Dr. Bonita previously held directorships at companies such as Tricida, Inc. (until 2023), SI-BONE, Inc. (2014-2019), and Loxo Oncology, Inc. (2013-2017), and began his career as a corporate finance analyst in healthcare investment banking at Morgan Stanley and UBS.[[1]](https://www.marketscreener.com/insider/DAVID-BONITA-A077UI/)[[3]](https://preludetx.com/david-bonita-md/)[[4]](https://imagenebio.com/team/david-p-bonita-m-d/) He holds an A.B. in Biological Sciences from Harvard University (1997) and joint M.D./M.B.A. degrees from Columbia University (2004).[[1]](https://www.marketscreener.com/insider/DAVID-BONITA-A077UI/)[[3]](https://preludetx.com/david-bonita-md/)[[4]](https://imagenebio.com/team/david-p-bonita-m-d/)
查看完整内部人档案 →